Please use this identifier to cite or link to this item: https://doi.org/10.1007/s10529-010-0423-5
DC FieldValue
dc.titleTherapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers
dc.contributor.authorXie, Z.
dc.contributor.authorChng, W.J.
dc.contributor.authorTay, K.G.
dc.contributor.authorLiu, S.C.
dc.contributor.authorZhou, J.
dc.contributor.authorChen, C.-S.
dc.date.accessioned2014-12-12T08:02:45Z
dc.date.available2014-12-12T08:02:45Z
dc.date.issued2011-02
dc.identifier.citationXie, Z., Chng, W.J., Tay, K.G., Liu, S.C., Zhou, J., Chen, C.-S. (2011-02). Therapeutic potential of antisense oligodeoxynucleotides in downregulating p53 oncogenic mutations in cancers. Biotechnology Letters 33 (2) : 221-228. ScholarBank@NUS Repository. https://doi.org/10.1007/s10529-010-0423-5
dc.identifier.issn01415492
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/117200
dc.description.abstractPurpose of work: Mutation of the p53 gene is the most common genetic alteration in human cancers. Our study proposes to rationally design a p53 antisense oligonucleotide (ASO) repository, which contains a series of ASOs containing single nucleotide differences to discriminate between each mutant and wild type (WT) p53. The Sfold software was used to predict target-accessibility and we designed an initial series of antisense oligonucleotides (ASO) that target the p53 mutants A161T, R175H and R249S. Western-blot analysis indicated that ASOs strongly inhibited the expression of p53 mutants in a panel of human tumor cell lines (SNU-449, SK-BR-3 and PLC/PRF/5) while having little effect on the expression of WT p53 (HepG2 cells). In three cancer lines harboring each of the p53 mutations, mutant-specific ASO treatment led to a dose-dependent inhibition of cell growth, cell viability, colony formation and invasion, and expression of mutant p53-dependent survival proteins. Our preliminary results indicate that a single nucleotide difference in ASOs can discriminate between mutant and WT p53. These observations support the hypothesis that a p53 ASO repository can be a potentially valuable tool to knock down oncogenic mutant p53 and warrant the testing of a p53 ASO repository in in vivo settings. © 2010 Springer Science+Business Media B.V.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1007/s10529-010-0423-5
dc.sourceScopus
dc.subjectAntisense oligodeoxynucleotide
dc.subjectCarcinoma
dc.subjectMutation
dc.subjectp53
dc.typeArticle
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.description.doi10.1007/s10529-010-0423-5
dc.description.sourcetitleBiotechnology Letters
dc.description.volume33
dc.description.issue2
dc.description.page221-228
dc.description.codenBILED
dc.identifier.isiut000286198700003
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

3
checked on Jul 21, 2021

WEB OF SCIENCETM
Citations

3
checked on Jul 21, 2021

Page view(s)

90
checked on Jul 12, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.